The effects of ethanol in combination with the alpha 2-adrenoceptor agonist dexmedetomidine and the alpha 2-adrenoceptor antagonist atipamezole on brain monoamine metabolites and motor performance of mice

European Journal of Pharmacology
J J Idänpään-HeikkiläT Seppälä

Abstract

The time course of the effects of ethanol alone and in combination with the selective alpha 2-adrenoceptor agonist dexmedetomidine and the alpha-adrenoceptor antagonist atipamezole was studied in NIH-Swiss mice. Core body temperature, rotarod performance, motility and changes in the noradrenaline, dopamine, and 5-hydroxytryptamine (5-HT) metabolite contents of different brain parts (limbic forebrain, striatum, lower brainstem, the rest of the forebrain + midbrain and hypothalamus) were measured. Atipamezole (3 mg/kg) attenuated the hypothermia induced by either ethanol (3 g/kg) alone or ethanol in combination with dexmedetomidine (0.3 mg/kg). Atipamezole shortened the duration of the ethanol-impaired and ethanol + dexmedetomidine-impaired rotarod performance. Further, atipamezole prevented the decreased motility due to the combined treatment with ethanol and dexmedetomidine. Ethanol increased 3-methoxy-4-hydroxyphenylethylene glycol (MHPG), homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) values. Dexmedetomidine alone decreased MHPG and 5-hydroxyindoleacetic acid (5-HIAA) concentrations and increased DOPAC and HVA values. Dexmedetomidine combined with ethanol resulted in a further increase in DOPAC and HVA val...Continue Reading

References

Nov 1, 1978·The Journal of Pharmacy and Pharmacology·S Liljequist, A Carlsson
Jan 31, 1979·Psychopharmacology·N G BacopoulosL S Van Orden
Apr 29, 1977·Psychopharmacology·J A Matchett, C K Erickson
Apr 1, 1976·British Journal of Pharmacology·F KaroumE Majchrowicz
Jan 1, 1976·Annals of the New York Academy of Sciences·R F Ritzmann, B Tabakoff
May 1, 1992·Trends in Pharmacological Sciences·H H Samson, R A Harris
Jul 1, 1992·Trends in Pharmacological Sciences·M BerlanM Lafontan
Nov 1, 1992·Brain Research Bulletin·C Milio, M G Hadfield
Jan 1, 1989·Life Sciences·R G ListerM Linnoila
Jun 1, 1986·British Journal of Addiction·D Nutt, P Glue
Jul 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·G Di Chiara, A Imperato
Jun 22, 1988·European Journal of Pharmacology·H ScheininM Scheinin
Dec 6, 1988·European Journal of Pharmacology·E MacDonaldM Scheinin
Jan 1, 1972·Psychopharmacologia·A CarlssonT H Svensson
Sep 1, 1974·Journal of Neurochemistry·W A Hunt, E Majchrowicz
Jan 1, 1973·Psychopharmacologia·A CarlssonB Waldeck
Apr 1, 1974·Life Sciences·S G Holtzman, F H Schneider
Aug 1, 1980·Naunyn-Schmiedeberg's Archives of Pharmacology·M Göthert, H Huth
Dec 1, 1982·Journal of Medicinal Chemistry·P B Timmermans, P A van Zwieten
Jan 1, 1984·British Journal of Pharmacology·A LivingstonB Morris
Jan 1, 1981·Pharmacology & Therapeutics·M Linnoila, M J Mattila
Jan 1, 1981·Psychopharmacology·G D Frye, G R Breese

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.